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ABSTRACT
Thiiobenzyhdrazide (Htbh) and its Cu(ll) complexes, [Cu(Htbh)2Cl2] and [Cu(tbh)2] were synthesized and
characterized by various physicochemical studies. In vivo and in vitro antitumour activity of Htbh,
[Cu(Htbh)zCl2] and [Cu(tbh)2] has been tested. LDso values were calculated for all the three compounds. It
was observed that the antitumour effect of [Cu(Htbh)Cl/] is maximum. Light microscopic study of the
treated tumour mass demonstrated that certain cellular degradation, suc], as disappearance of mitotic figures,
loss in cellular compactness, distortion of nucleus and disruption of cytoplasmic boundaries, takes place in
the tumour region of complex treated mice. Further, tumour bearing mice administered with Cu(II)
complexes showed reversal oftumour growth associated induction of apoptosis in lymphocytes.
INTRODUCTION
During the past decade atter the successful achievement of cis-dichlorodiammine platinum(ll) (cisplatin),
a number of derivatives of thiosemicarbazone, such as 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone)
copper complexes (Cu-KTS), have been found to exhibit antitumour activity/1,2/by binding with DNA/3/.
In addition, the copper complexes of thiosemicarbazide inactivate lambda phage infectivity and transaction
by lambda DNA/4/, and inhibit the activity of RNA dependent DNA polymerase of Rous sarcoma virus/5/.
Thiosemicarbazones of l-formylisoquinoline and 2-formylpyridine and their derivatives were also
demonstrated as effective against animal tumour /6,7/ at the molecular level by inhibiting the enzyme
ribonucleoside diphosphate reductase and synthesis of DNA/8-10/. Many chemotherapeutic agents have also
been reported to possess immunomodulatory properties/11,12/. However, the immunomodulatory potential
of the metal complexes with antitumour activity has not been explored adequately. Although thiohydrazides
are structurally quite similar to thiosemicarbazides, scarcity of work on the antineoplastic and immuno-
modulatory activity of transition metal complexes of thiohydrazides prompted us to study the activity of
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transition metal complexes of thiobenzhydrazide (C6HsC(S)NHNH2). In the present investigation we report
the synthesis, characterization and antitumour activity of Cu(ll) complexes of thiobenzhydrazide (Htbh).
Further, we also investigated the immunomodulatory action of these complexes on Dalton’s Lymphoma (DL)
bearing host.
MATERIALS AND METHODS
Elemental analyses, magnetic susceptibility, infrared, electronic and ESR spectra of the complexes were
recorded as described elsewhere/12/.
Synthesis of ligand
Carboxymethyldithiobenzoate (2.0g) was dissolved in 1N-NaOH (10 mL, equi) and 10 mL water. The
solution was cooled in ice and hydrazine hydrate (0.44g, 2 equi) was added. The thiobenzhydrazide separated
immediately and the orange colour of the solution disappeared. A few drops of 1N-HC1 were added to the
above solution to bring it to pH 5-6 and the mixture was kept in ice for one hour. The product thus obtained
was filtered off, washed with water and dried in vacuo. The crude product was recrystallized from hot
ethanol (rap 73-75 C) /13/ (Fig. 1).
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Fig. 1: Thiobenzhydrazide (Hbth)
Synthesis of Cu(ll) complexes
[Cu(Htbh)Cl] was prepared by adding an ethanol solution of copper(ll) chloride, containing a few drops
of dil. HCI to the ethanol solution of the thiobenzhydrazide in a 1:2 molar ratio. The complex which
precipitated immediately, was filtered by suction, washed with ethanol and dried in vacuo. [Cu(tbh)], on the
other hand, was prepared by adding an ethanol solution of the ligand (thiobenzhydrazide) to an aqueous
solution of copper(ll) acetate in a 1:2 molar ratio in the presence of sodium acetate (0.5g) and digesting the
reaction mixture for 30-60 min. The complex thus obtained was filtered by suction, washed successively
with water, ethanol and finally with ether, and dried in vacuo (Fig. 2).
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Fig. 2: Proposed structure of Cu(ll) complexes
Test for toxicity
DL cells were transplanted in BALB/e mice by an intraperitoneal injection of 5 105 cells/mouse. On day
three of transplantation of mammal3, gland tumour, the test compounds in different doses were injected IP as
a single injection. Five animals were used per dose level. Toxic doses were estimated on the basis of
survivals on the fifth day of injection (Table I).
Table
Toxic Doses of Htbh and its Cu(ll) Complexes
Complex HNTD mg/kg
body weight
68
TDH mg/kg
body weight
90
LDso mg/kg
bodyweigh
250 Htbh
[Cu(tbh)2] 50 75 200 2.3
[Cu(Htbh)2Cl2] 30 60 150 1.2
IDso
___m
5.2
HNTD (Highest Non-Toxic Dose): The dose which can be administered without causing hematologic
chemical or pathologic abnormalities; doubling this dose causes toxicity.
TDH (Toxic Dose High): Dose which causes abnormalities; doubling this dose produces lethality.
LDs0 (Lethal Dose 50): Dose that causes death in 50% of animals.
IDs0 (Inhibition Dose 50): Dose that causes 50% inhibition oftumour growth in vitro.
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Dose schedule
Eight to twenty mice were used for each set of experiments. Htbh, [Cu(tbh)2] and [Cu(Htbh)2Cl2] were
injected only once IP at appropriate dose levels in mice on day three after tumour transplantation. Compound
suspension was freshly prepared in 30% ethanol. Controls were injected with the same volume of 30%
ethanol. On alternate days, up to 4 weeks tumour bearing animals were weighed to detemaine the change in
body weight. The acute toxicities of the complexes were determined after 48h of compound injection in
tumour bearing mice. LDs0 values obtained are given in Table i.
Evaluation of antitumour activity
The therapeutic effectiveness of Htbh, [Cu(tbh)2] and [Cu(Htbh)2Cl] against DL bearing mice was
assessed from the mean survival time of the treated animals (excluding tumour free survivors) divided by
mean life span of untreated mice multiplied by 100, giving the T/C percentage. A T/C value of 115 indicates
significant activity, wherewas a value for T/C > 125 indicates that the complex is worthy of testing in other
tumour systems.
Histological study
Animals from both control and treated batches were killed at 2-day intervals up to 6 days. Tumour tissue
with liver, kidney and spleen was fixed in Bouin’s fluid (aqueous), dehydrated, kept in cedar wood soil for 3
days and embedded in paraffin. Paraffin sections of 5 lam were cut, stained in Ehrlich’s hematoxylin eosin
stain, dehydrated, cleared in xylene, and mounted in DPX. Slides were studied under the light microscope.
All other biological studies were carried out as described elsewhere/12/.
RESULTS AND DISCUSSION
The molar conductance values of the complexes in DMF demonstrate their non-ionic nature. The
magnetic moments of 1.86 2.20 B.M. for Cu(Ii) complexes correspond to the presence of one unpaired
electron. The electronic spectrum of [Cu(Htbh)2Cl2] shows bands at 10530, 16000 and 25000 cm"l, which
were assigned to 2B 2A 2B Ig -’ Ig(Vl); Ig 2B2g(V2) and 2Big --
2Eg(v3) transitions, respectively. The positions
of these bands and their assignment suggest distorted octahedral geometry. A band at 20,410 cm
"1 in the
spectrum of [Cu(tbh)2] indicates its square planar geometry. The ESR spectra of [Cu(Htbh)2Cl2] and
[Cu(tbh)2] in CHCI3 at 77 K yield a broad signal, from which gio values have been found to be 2.1221 and
2.0548, respectively. The IR spectrum of the ligand displays bands at 3400, 3220, 1655 and 980 cm, which
may be assigned to v(NH), v(NH)2, 13(NH)2 and v(N-N) modes, respectively. The v(NH)2 band shows
negative shifts of 80 and 60 cm in [Cu(Htbh)2Cl2] and [Cu(tbh)2], respectively, whereas the v(N-N) band
shows a positive shif6t of 40- 45 cm, indicating that the nitrogen of the amino group is involved in
bonding. Thioamide bands and II undergo positive shifts showing bonding through thione/thiol sulfur.
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However, thioamide band-IV [mainly due to v(C=S)] undergoes a negative shif of 40 cm" in
[Cu(Htbh)2CI2], indicating bonding through ’thione’ sulfur. This band is, however, found to be absent in
[Cu(tbh)2] and in place of this a new band appears at 720 cm"t, due to v(C-S), which indicates bonding
through ’thiolato’ sulfur/13/(Fig. 2).
ANTITUMOUR STUDIES
To study the antitumour activity, the ligand and its Cu(ll) complexes were administered (60 and 120
mg/kg of mouse weight) to Dalton’s Lymphoma (DL) bearing mice. Toxic doses were evaluated in terms of
HNTD, TDH and LDs0 (Table 1). Maximum in vivo antitumour activity was found for [Cu(Htbh)2CI2]. The
enhanced activity of the chloro complex as compared to [Cu(tbh)2] may be attributed to the presence of labile
chlorine, as is observed in the case of cisplatin. Also, the number of DL bearing mice administered with
[Cu(Htbh)2CI2] surviving for more than 3 months was found to be maximum (Table 2). We checked the life
prolongation effect in DL bearing mice administered with phosphate buffer saline (PBS) alone or containing
ligand or its Cu(ll) complexes. As shown in Table 2, maximum % T/C was found for [Cu(Htbh)2CI2]
followed by [Cu(tbh)2], whereas the ligand alone failed to increase significantly the life span of tumour
bearing mice. Increase in the value of% T/C indicates a prolongation of the life of tumour bearing mice and
suggests that such an effect could result either from the direct cytotoxic/cytostatic action of the complexes on
tumour cells or from the activation of certain host derived antitumour defense mechanism(s). Therefore, in
the next part of the study we carried out investigations to understand the mechanism(s) underlying the
prolongation ofthe life span oftumour bearing mice treated with Cu(ll) complexes.
Part of the evidence comes from the experiments in which tumour cells, incubated in the presence or
absence of metal complexes, were checked for their effect on viability by MTT assay, in which 3,(4,5-
Table !!
Screening Data for Htbh, [Cu(tbh)2] and [Cu(Htbh)2Cl2] in the mammary gland
tumour bearing mice ofC3h Jax strain
Dosage in
mg/kg weight
ofmouse
60 IP
120 IP
Number of mice injected
10/10
8/8
II
10/10
20/20
III
10/10
20/20
Post inoculation life span
115
120
Number ofmice surviving
(% T/C) more th.an thr.ee months
d
I1 I11 II III
178 210 2(,1,0) 2(!0) ,8(10)
185 218 3(8) 5(20) ,15(20)
a. Ten injections on alternate days of the following dose was given.
b. Average weight change from day of drug treatment to 30 days.
c. In calculating average survival time, mice surviving 3 months or more were not included.
d. Number in parentheses indicates total number ofmice injected.
e. Treatment was initiated on day three after tumourtransplantation.
Htbh; II [Cu(tbh)2]; III [Cu(Htbh)2Ci2]
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dimethylthiazol-2-yl)-2,5-diphenyl tetmzolium bromide) is metabolised to an insoluble coloured formazan
salt by mitochondrial enzyme activity of SDH in living cells/14/. As shown in Table 1, treatment of tumour
cells with [Cu(Htbh)2Cl2] caused maximum, growth inhibition, followed by [Cu(tbh)2] and. the ligand,
indicating an inhibition of the SDH activity. These results thus indicate a possible decline of the overall
metabolic activity of the tumour cells with a concomitant inhibition of the activity of the enzymes involved in
halting the process of respiration.
Although the metal complexes showed cytostatic effects on the tumour cells in vitro, these results do not
necessarily indicate if these cells are actually killed by the direct action of the metal complexes. To check this
in the next part of the investigation we studied the effect of the metal complexes on tumour cell killing to
80
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Fig. 3a:
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Htbh [Cu(Htbh)2012] [Cu(tbh)2]
[Cu(tbh)2
Effect of Htbh and its Cu(ll) complexes on the induction of apoptosis in tumour cells. DL cells
were incubated in medium alone or containing Htbh or its Cu(ll) complexes (10 lag/mL) for 24 h
and the number of cells showing apoptotic morphology was enumerated. Values are the mean of
three experiments.
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identify the mode of cell death. The results suggest that apoptosis induced in tumour cells treated with
[Cu(Htbh)zC12] was found to be most effective in the induction of tumour cell apoptosis (Fig. 3a). The
mechanism of the induction of apoptosis remains poorly understood and is thought to be dependent on
multiple mechanism(s) ultimately culminating in the activation ofDNA cleaving endonucleases/15/. Indeed,
results presented in Fig. 3b show that [Cu(Htbh)2C12] and [Cu(tbh)] cause an increase in the percentage of
specific DNA fragmentation, a hallmark feature of apoptosis, indicating that these metal complexes may
induce apoptosis culminating in the activation of endonucleases causing DNA fragmentation.
Light microscopic studies reveal that untreated DL cells show compact cellular organization, in which the
cells have an oval shaped large nucleus with a single prominent nucleolus. The cytoplasma is well developed
and chromatin material is prominent. Cells in the various stages of mitotic division could be seen. A few
leucocytes and lymphocytes were observed. The treated animals revealed the loss of cellular compactness of
the tumour mass and cytoplasm appears to be distorted with vesicle appearances. The cell walls of rnost of
the cells were ruptured, nuclei became translucent and lost their shapes. The nucleoli material became more
8o
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Effect of Htbh and its Cu(II) complexes on % DNA fragmentation of tumour cells. DL cells were
incubated in medium alone or containing Htbh or its Cu(II) complexes (10 lag/mL) for 24 h and
the % DNA fragmentation was evaluated. Values are the mean of three experiments.
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condensed. The high dose treatment was more effective and cell cytoplasm and the cytoplasmic boundaries
between the cells were disrupted. The nucleus became more translucent and nuclear material was in the form
of condensed granules. In the case of [Ctl(Htbh)2Cl2] a more effective result was obtained, in which the
completely destroyed cytoplasmic mass was prominent. A large number of leucocytes, lymphocytes and
macrophages appeared. Only a few mitotic figures were observed after ten doses of treatment. The results
reported in this study showed that [Cu(Htbh)zClz] has a strong antitumour effect and also plays an important
role in the tumour regression.
The appearance of lymphocytes and macrophages in the tumour mass after the treatment with metal
complexes also suggests that probably the host’s immune defence mechanism is increased. This prompted us
to investigate if the administration of metal complexes could reverse tumour growth associated induction of
apoptosis in various hematopoietic cells. For this, DL bearing mice were administered with Cu(II)
complexes, and the percentage of apoptotic thymocyte, splenocyte and bone marrow cells were enumerated.
As shown in Fig. 4a, administration of metal complexes in tumour bearing mice resulted in the inhibition of
100]
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40
30
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Fig. 4a"
Normal Mice Tumour Bearing Mice TBM + [Htbh] TBM + [Cu(tbh)2] TBM + [Cu(Htbh)2CI2]
(TAM)
B Thymocytes B Splenocytes Bone Marrow Cells
Effect of in vivo administration of Htbh or its Cu(II) complexes on the induction of apoptosis in
thymocytes, splenocytes and bone marrow cells of normal or tumour bearing mice treated with
ligand or its metal complexes. These cells were enumerated for the number of cells showing
apoptotic morphology. Values are the mean of three experiments.
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tumour associated apoptosis of thymocyte, splenocyte and bone marrow cells. Similar results were obtained
for percentage DNA fragmentation as well (Fig. 4b). The reversal of tumour growth associated inducation of
apoptosis of hematopoietic cells by metal complexes is predicted to be due to reduction of tumour load
resulting from the cytotoxic effect of metal complexes on tumour cells, leading to a decrease in the tumour
associated concentration of apoptotic factors and by the direct protective effect of metal complexes on the
hematopoietic cells. Although not very clear, the probability of the latter could be due to the fact that metal
complexes can bind to DNA and several proteins in cells, which could result in the protective effect.
The present study shows that the Cu(ll) complexes of thiobenzhydrazide are not only active antitumour
agents, but are also immunopotentiating agents, on account of their ability to reverse tumour associated
immunosuppression. The importance of such work lies in the possibility that the new complexes might be
more efficacious drugs for therapeutic use against tumours in view of their dual mechanism of action.
lOO
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Tumour Bearing Mice TBM + [Htbh] TBM + [Cu(tbh)2] TBM + [Cu(Htbh)2Cl2)]2] TBM +
(TBM) [Cu(HTbh)2
B Thymocytes B Splenocytes ! Bone Marrow Cells
Effect of in vivo administration of Htbh or its Cu(ll) complexes on % DNA fragmentation of
thymocytes, splenocytes and bone marrow cells of normal or tumour bearing mice treated with
ligand or its metal complexes. These cells were checked for % DNA fragmentation. Values are the
mean of three experiments.
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